tetano
Editor, Senior Moderator
J Infect Dis
. 2021 Jul 19;jiab377.
doi: 10.1093/infdis/jiab377. Online ahead of print.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019
Ravindra Ganesh[SUP] 1 [/SUP], Lindsey M Philpot[SUP] 1 [/SUP], Dennis M Bierle[SUP] 1 [/SUP], Ryan J Anderson[SUP] 1 [/SUP], Lori L Arndt[SUP] 2 [/SUP], Richard F Arndt[SUP] 2 [/SUP], Tracy L Culbertson[SUP] 3 [/SUP], Molly J Destro Borgen[SUP] 1 [/SUP], Sara N Hanson[SUP] 3 [/SUP], Brian D Kennedy[SUP] 4 [/SUP], Brian B Kottke[SUP] 3 [/SUP], Jennifer J Larsen[SUP] 1 [/SUP], Priya Ramar[SUP] 1 [/SUP], Jordan K Rosedahl[SUP] 1 [/SUP], Maria Teresa Seville[SUP] 5 [/SUP], Leigh L Speicher[SUP] 6 [/SUP], Sidna M Tulledge-Scheitel[SUP] 1 [/SUP], Caroline G Wilker[SUP] 7 [/SUP], Raymund R Razonable[SUP] 1 [/SUP], Monoclonal Antibody Treatment Program
Affiliations
Abstract
Background: Bamlanivimab and casirivimab-imdevimab are authorized for treatment of high-risk patients with mild to moderate coronavirus disease-2019 (COVID-19). We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes.
Methods: Adult patients who received monoclonal antibody from November 19, 2020 to February 11, 2021 were selected and divided into those who received bamlanivimab (n=2747) and casirivimab-imdevimab (n=849). The 28-day all-cause and COVID-19-related hospitalizations were compared between the groups.
Results: The population included 3596 patients; median age was 62 years; and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All cause- and COVID-19-related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all cause- and COVID-19-related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted HR, 1.4, 95% CI 0.9-2.2 and 1.6, 95% CI 0.8-2.7, respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization.
Conclusion: This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
Keywords: bamlanivimab; casirivimab; covid-19; hospitalization; outcomes.
. 2021 Jul 19;jiab377.
doi: 10.1093/infdis/jiab377. Online ahead of print.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019
Ravindra Ganesh[SUP] 1 [/SUP], Lindsey M Philpot[SUP] 1 [/SUP], Dennis M Bierle[SUP] 1 [/SUP], Ryan J Anderson[SUP] 1 [/SUP], Lori L Arndt[SUP] 2 [/SUP], Richard F Arndt[SUP] 2 [/SUP], Tracy L Culbertson[SUP] 3 [/SUP], Molly J Destro Borgen[SUP] 1 [/SUP], Sara N Hanson[SUP] 3 [/SUP], Brian D Kennedy[SUP] 4 [/SUP], Brian B Kottke[SUP] 3 [/SUP], Jennifer J Larsen[SUP] 1 [/SUP], Priya Ramar[SUP] 1 [/SUP], Jordan K Rosedahl[SUP] 1 [/SUP], Maria Teresa Seville[SUP] 5 [/SUP], Leigh L Speicher[SUP] 6 [/SUP], Sidna M Tulledge-Scheitel[SUP] 1 [/SUP], Caroline G Wilker[SUP] 7 [/SUP], Raymund R Razonable[SUP] 1 [/SUP], Monoclonal Antibody Treatment Program
Affiliations
- PMID: 34279629
- DOI: 10.1093/infdis/jiab377
Abstract
Background: Bamlanivimab and casirivimab-imdevimab are authorized for treatment of high-risk patients with mild to moderate coronavirus disease-2019 (COVID-19). We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes.
Methods: Adult patients who received monoclonal antibody from November 19, 2020 to February 11, 2021 were selected and divided into those who received bamlanivimab (n=2747) and casirivimab-imdevimab (n=849). The 28-day all-cause and COVID-19-related hospitalizations were compared between the groups.
Results: The population included 3596 patients; median age was 62 years; and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All cause- and COVID-19-related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all cause- and COVID-19-related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted HR, 1.4, 95% CI 0.9-2.2 and 1.6, 95% CI 0.8-2.7, respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization.
Conclusion: This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
Keywords: bamlanivimab; casirivimab; covid-19; hospitalization; outcomes.